Business Wire

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric ...
Nasdaq

Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety

Reviva Pharmaceuticals announced positive results from its Phase 3 RECOVER open-label extension study evaluating brilaroxazine for treating schizophrenia. The study demonstrated robust and sustained ...
Medscape

Positive Phase 3 Results for Novel Antipsychotic in Schizophrenia

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...
Business Wire

Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety ...
MedPage Today on MSN

Novel Antipsychotic Shows Promise in Acute Schizophrenia

Downsides with current options leave a large unmet need for new therapies, researcher says ...
Healio

Positive efficacy results reported in phase 3 study of schizophrenia injectable

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tev-‘749 is a subcutaneous injectable for adults with ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Healio

Results positive in study of PDE4 inhibitor for cognitive impairment in schizophrenia

Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...
Science Daily

New hope for schizophrenia: iTBS over the left DLPFC improves negative and cognitive symptoms

Theta burst stimulation (TBS) is a non-invasive brain stimulation technique known for modifying human behavior and treating neurological diseases. A group of scientists conducted a systematic review ...